Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis.
Eur J Neurol
; 12(11): 869-78, 2005 Nov.
Article
em En
| MEDLINE
| ID: mdl-16241976
ABSTRACT
Glatiramer acetate (GA) treatment for relapsing remitting multiple sclerosis (RRMS) leads to decreased GA-specific proliferative responses and a Th2 cytokine shift. To study a possible correlation between immunological and clinical responses to GA therapy, we prospectively followed RRMS patients clinically, by magnetic resonance imaging and by primary immunological assays. Fluctuation of GA-specific proliferative responses was significantly lower in treatment responders than in untreated patients, and GA-specific proliferative responses were increased during relapses. These associations suggest a possible causal relationship between immunological and clinical responses to GA therapy. Primary proliferation assays may thus be a useful marker for treatment response.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Peptídeos
/
Citocinas
/
Esclerose Múltipla Recidivante-Remitente
/
Tolerância Imunológica
Idioma:
En
Ano de publicação:
2005
Tipo de documento:
Article